A recent study investigated the combination of neratinib with cetuximab in quadruple-WT (KRAS, NRAS, BRAF, PIK3CA) metastatic CRC patients who had previously shown resistance to cetuximab or panitumumab. This evidence concerns the gene BRAF and colorectal carcinoma.